

Fabian Maass

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4348003/publications.pdf>

Version: 2024-02-01

12
papers

279
citations

1039880

9
h-index

1199470

12
g-index

12
all docs

12
docs citations

12
times ranked

437
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteomic analysis of tear fluid reveals disease-specific patterns in patients with Parkinson's disease â€” A pilot study. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 3-9.	1.1	57
2	Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2018, 145, 342-351.	2.1	39
3	Cerebrospinal fluid biomarker for Parkinson's disease: An overview. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 60-66.	1.0	32
4	Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinsonâ€™s Disease. <i>Cells</i> , 2019, 8, 105.	1.8	30
5	Increased alpha-synuclein tear fluid levels in patients with Parkinsonâ€™s disease. <i>Scientific Reports</i> , 2020, 10, 8507.	1.6	24
6	Selenium speciation analysis in the cerebrospinal fluid of patients with Parkinsonâ€™s disease. <i>Journal of Trace Elements in Medicine and Biology</i> , 2020, 57, 126412.	1.5	23
7	Elemental fingerprint: Reassessment of a cerebrospinal fluid biomarker for Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 134, 104677.	2.1	23
8	Multi-omic landscaping of human midbrains identifies disease-relevant molecular targets and pathways in advanced-stage Parkinson's disease. <i>Clinical and Translational Medicine</i> , 2022, 12, e692.	1.7	22
9	MicroRNAs from extracellular vesicles as a signature for Parkinson's disease. <i>Clinical and Translational Medicine</i> , 2021, 11, e357.	1.7	14
10	The relevance of synuclein autoantibodies as a biomarker for Parkinson's disease. <i>Molecular and Cellular Neurosciences</i> , 2022, 121, 103746.	1.0	8
11	Cerebrospinal Fluid Ironâ€”Ferritin Ratio as a Potential Progression Marker for Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2967-2969.	2.2	4
12	Validation of Plasma Neurofilament Light Chain as a Marker for Synucleinopathies. <i>Movement Disorders</i> , 2021, 36, 2701-2703.	2.2	3